COMMUNIQUÉS West-GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/08/2025
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired [...]
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
06/08/2025
Conference call today at 9:00 am ET 2Q 2025 revenues of $76.5M, +6% v. 2Q 2024 YTD 2025 revenues of $154.9M, +12% v. YTD 2024 Advanced pipeline: Submitted sBLA for Afrezza ® in pediatric population MNKD-101: NTM global [...]
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
06/08/2025
Strengthens MannKind’s capital structure with flexible, long-term, non-dilutive funding MannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif. and NEW YORK, Aug. 06, 2025 (GLOBE [...]
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
06/08/2025
Peer-reviewed publication highlights ATI-1701’s robust protection against aerosolized Francisella tularensis exposure in multiple animal models HALIFAX, Nova Scotia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics [...]
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury
06/08/2025
First patient successfully completes dosing at Toronto General Hospital St. Michael’s Hospital is expected to be the next Canadian clinical site activated Arch is looking for additional clinical sites in North America [...]
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
06/08/2025
WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with [...]
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
06/08/2025
Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo [...]
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
06/08/2025
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr [...]
FDA Petition to Ban Mercury Dental Fillings submitted by IAOMT and DAMS INC.
06/08/2025
LAKELAND, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- The International Academy of Oral Medicine and Toxicology (IAOMT) and the Dental Amalgam Mercury Solutions (DAMS INC) have joined forces to petition the Food and Drug [...]
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
06/08/2025
CELEBRATION, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
FOXO TECHNOLOGIES INC. ANNOUNCES EXECUTION OF A NON-BINDING ACQUISITION AGREEMENT FOR AN ASSISTED-LIVING FACILITY IN SOUTH FLORIDA FOR A TOTAL CONSIDERATION OF $22 MILLION
06/08/2025
WEST PALM BEACH, FLORIDA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“ FOXO ” or the “ Company ”) announces that it has executed a non-binding acquisition agreement to acquire an [...]
Pure Harvest Corporate Group Eliminates All Debt and Enters New Phase of Strategic Growth
06/08/2025
GREENWOOD VILLAGE, Colo., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Pure Harvest Corporate Group, Inc. (OTC: PHCG), a diversified holding company focused on acquiring and revitalizing undervalued businesses, is pleased to [...]
Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
06/08/2025
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have [...]
Glass House Brands to Host Second Quarter 2025 Conference Call on August 13, 2025
06/08/2025
LONG BEACH, Calif. and TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
06/08/2025
EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
06/08/2025
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
Cardurion Pharmaceuticals Completes Enrollment in Phase 2 CYCLE Trials Evaluating CRD-750, a Novel PDE9 inhibitor, in Heart Failure
06/08/2025
CRD-750 is the first clinical-stage PDE9 inhibitor to be evaluated in patients in both types of chronic heart failure The CYCLE-1-REF trial is evaluating patients with heart failure with reduced ejection fraction (HFrEF [...]
Sofwave to Participate in 10th Annual Needham Virtual MedTech & Diagnostics Conference
06/08/2025
SAN CLEMENTE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today [...]
PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results
06/08/2025
PRINCETON, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets [...]

Pages